GFC Life Science Reports Strong Q1 2026 Results with Revenue and Profit Growth, R&D Investment Expansion

Q1 2026 revenue of 5.04 billion KRW, up 12.2% YoY from 4.49 billion KRW
Operating profit of 464 million KRW, up 20.2% YoY from 386 million KRW
Net profit of 477 million KRW, up 60% YoY from 298 million KRW, continuing turnaround
Basic EPS of 90 KRW, up from 68 KRW in Q1 2025
R&D expenses of 688 million KRW (13.7% of revenue), up 46% YoY from 471 million KRW
Total assets of 35.8 billion KRW, liabilities 11.2 billion KRW, equity 24.6 billion KRW, debt ratio 45.6%
Cash and cash equivalents of 5.6 billion KRW, down from 7.5 billion at year-end 2025; long-term borrowings increased to 8.0 billion KRW (from 7.0 billion)
Holds 121 patents and 117 trademarks, strengthening exosome and microbiome technology competitiveness
Deficit offset of 7.44 billion KRW through capital reserve reduction, improving financial structure
Issued 50,400 new shares via stock option exercise, increasing paid-in capital to 2.65 billion KRW

ADVERTISEMENT (250px+)